Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older

First novel steroid-free topical with a new mechanism of action approved for plaque psoriasis in over 25 yearsFirst ZORYVE approval outside of the U.S. marks key milestone for Arcutis WESTLAKE... | April 28, 2023

Related Keywords

Canada ,United States ,Canadian ,Melinda Gooderham ,Frank Watanabe ,Arcutis Biotherapeutics ,Amanda Sheldon ,Queen University ,Facebook ,Skin Centre For Dermatology ,Skin Research Centre In Peterborough ,Head Of Corporate Communications ,Nasdaq ,Twitter ,Linkedin ,Exchange Commission ,Arcutis Biotherapeutics Inc ,Health Canada ,Assistant Professor ,Medical Director ,Principal Investigator ,Private Securities Litigation Reform Act ,Nc Stock Exchange ,News ,Information ,Press Release ,First ,Novel ,Ropical ,Ith ,Few ,Mechanism ,F ,Action ,Approved ,Or ,Plaque ,Psoriasis ,N ,Dover ,5 ,Earsfirst ,Oryve ,Approval ,Outside ,The ,Parks ,Key ,Milestone ,Rcutis Arqt Us03969k1088 ,